Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drop of blood predict disease years before it strikes?

NCT ID NCT07743021

Knowledge-focused Sponsor: Center for Molecular Fingerprinting Research Nonprofit LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study is collecting blood samples and health data from 15,000 symptom-free adults over 40 to understand what healthy aging looks like at the molecular level. By tracking participants over time, researchers hope to establish normal ranges for thousands of blood markers and identify early warning signs for major diseases like cancer, heart disease, and diabetes. The goal is to create a 'molecular fingerprint' that could one day lead to earlier detection and prevention of these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to earlier detection of diseases like cancer, heart disease, and diabetes through simple blood tests, potentially improving prevention and treatment outcomes.
What could go wrong
This is an observational study, not a treatment trial. It will take years of follow-up to see if any new biomarkers are reliable, and findings may not translate into practical tests quickly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2021

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population include healthy participants who are managed by primary healthcare professionals in Hungary, in any parts of the country.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Low- and Moderate-risk Cohort: Inclusion Criteria: 1. Signed informed consent form (ICF) of the study. 2. Age \> 40 years. 3. Willingness to fill in the study questionnaire. 4. No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed. 5. Willingness to participate in future visits. Exclusion Criteria: 1. Self-reported pregnancy (no test). 2. Indications of clinically relevant medical conditions in self-reported healthy subjects. 3. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure. 4. Any conditions preventing blood-draw. 5. Vulnerable subjects. 6. Foreseeable lack of compliance. 7. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 8. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and / or further pharmaceutical product administration is planned. 9. Vaccination within the last 14 days. High-risk Cohort: Inclusion Criteria: 1. Signed informed consent form (ICF) of the study. 2. Age \> 50 years. 3. Willingness to fill in the study questionnaire. 4. Willingness to participate in future visits and medical investigations, the presence of at least 2 of the following 3 risk factors (inclusion criteria #5-7): 5. Hypertension, receiving antihypertensive treatment. 6. Dyslipidemia/ Hypercholesterolemia (\>5.2mmol/L total cholesterol level), on or not on statin-treatment. 7. Active or former smoker, with smoking history of at least 20 pack-years, and/or the presence of intermediate lung nodule on prior LDCT testing. 8. No clinically relevant symptoms as assessed by the investigator; subjects with existing medical conditions may be eligible given that they are symptom free and that treatment of the condition is well documented. Exclusion Criteria: 1. Self-reported pregnancy (no test). 2. Cardiovascular disease (including obstructive coronary artery disease, peripheral artery disease, aortic aneurysm) or other clinically significant heart disease (congenital, valvular heart disease, cardiomyopathy, heart failure and heart disease requiring ICD \[implantable cardioverter defibrillator\] or pacemaker therapy). 3. Interstitial lung disease or severe COPD (chronic obstructive pulmonary disease) in GOLD stages 3 or 4. 4. Active cancer or malignant disease with less than 5 years history of remission. 5. Indications of clinically relevant medical conditions in self-reported healthy subjects, especially if (a) the condition requires regular or constant specialist checkups, or (b) pharmacological therapy indicates the presence of significant NCDs or multimorbidity, i.e., chronic polypharmacy (use of 5 or more medications at enrollment or over the last 6 months), or drug therapy necessitating a specialist input for initiation or management (e.g., combined anti-diabetic treatment with two or more medications). 6. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure. 7. Any conditions preventing blood-draw or CT scans. 8. Vulnerable subjects. 9. Foreseeable lack of compliance. 10. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 'High-risk' subjects enrolled in the low- and moderate-risk arm of the H4H study might be reallocated to the high-risk study arm after the first 4-5 visits. 11. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and/or further pharmaceutical product administration is planned. 12. Vaccination within the last 14 days of sample collection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease (ascvd) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease cancer cardiovascular disorder chronic obstructive pulmonary disease coronary artery disorder diabetes mellitus lung cancer lung neoplasm neoplasm non-small cell lung carcinoma Noncommunicable Diseases peripheral arterial disease prediabetes syndrome stroke disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerotic cardiovascular disease (ascvd) Cancer Cardiovascular diseases (CVD) Chronic obstructive pulmonary disease (COPD) Chronic respiratory diseases Coronary artery disease (CAD) Diabetes mellitus (DM) Lung cancer (NSCLC) Neoplams Non-communicable diseases (NCD) Peripheral artery disease (PAD) Prediabetes Stroke (CVA) or tia Type 2 diabetes (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    25 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • 01_OVSZ Budapest_Hungarian National Blood Transfusion Service, Central Hungarian Regional Blood Transfusion Center

    SUSPENDED

    Budapest, 1113, Hungary

  • 02_PTE Pécs_University of Pécs, Centre for Occupational Health and Hygiene of the University of Pécs Clinical Centre

    ACTIVE_NOT_RECRUITING

    Pécs, 7624, Hungary

  • 03_VVM Veszprém_Vita Verum Medical LLP

    RECRUITING

    Székesfehérvár, 8000, Hungary

    Contact Email: •••••@•••••

  • 04_DRC Balatonfüred_Drug Research Center LLC

    SUSPENDED

    Balatonfüred, 8230, Hungary

  • 05_DE Debrecen_University of Debrecen Clinical Centre, Institute for Primary Care and Health Promotion of Debrecen

    ACTIVE_NOT_RECRUITING

    Debrecen, 4032, Hungary

  • 07_SE Budapest_Semmelweis University, Occupational Health Service

    ACTIVE_NOT_RECRUITING

    Budapest, 1085, Hungary

  • 08_Qualiclinic Budapest_Qualiclinic LLC

    RECRUITING

    Budapest, 1036, Hungary

    Contact Email: •••••@•••••

  • 09_Derma-B Debrecen_DERMA-B LLC

    ACTIVE_NOT_RECRUITING

    Debrecen, 4031, Hungary

  • 11_UNO Med Budapest_UNO MEDICAL TRIALS LLC

    ACTIVE_NOT_RECRUITING

    Budapest, 1152, Hungary

  • 13_TP Győr_Trial Pharma LLC Győr

    SUSPENDED

    Győr, 9026, Hungary

  • 14_TP Békéscsaba_Trial Pharma LLC Békéscsaba

    RECRUITING

    Békéscsaba, 5600, Hungary

  • 15_TP Orosháza_Trial Pharma LLC Orosháza

    ACTIVE_NOT_RECRUITING

    Orosháza, 5900, Hungary

  • 16_TP Gyula_Trial Pharma LLC Gyula

    RECRUITING

    Gyula, 5700, Hungary

  • 17_TP Szeged_Trial Pharma LLC Szeged

    RECRUITING

    Szeged, 6726, Hungary

  • 18_TP Sopron_Trial Pharma LLC Sopron

    RECRUITING

    Sopron, 9400, Hungary

  • 19_TP Csorna_Trial Pharma LLC Csorna

    SUSPENDED

    Csorna, 9300, Hungary

  • 20_TP Budapest_Trial Pharma LLC Budapest

    ACTIVE_NOT_RECRUITING

    Budapest, 1119, Hungary

  • 21_TP Nyíregyháza_Trial Pharma LLC Nyíregyháza

    ACTIVE_NOT_RECRUITING

    Nyíregyháza, 4400, Hungary

  • 22_MÁV Budapest_Railway Health Care Nonprofit Public Benefit Ltd.

    RECRUITING

    Budapest, 1062, Hungary

    Contact Email: •••••@•••••

  • 23_MÁV Miskolc_Hungarian State Railways Clinic in Miskolc

    RECRUITING

    Budapest, 3527, Hungary

    Contact Email: •••••@•••••

  • 24_MÁV_Szeged_Hungarian State Railways Clinic in Szeged

    RECRUITING

    Szeged, 6726, Hungary

    Contact Email: •••••@•••••

  • 25_DermaMed_DermaMed Research LCC.

    RECRUITING

    Orosháza, 5900, Hungary

  • 26_BAZ Miskolc_Borsod-Abaúj-Zemplén County Central Hospital and University Teaching Hospital

    RECRUITING

    Miskolc, 3526, Hungary

  • 28_Kaposvár Kh_Somogy County Kaposi Mór Teaching Hospital

    RECRUITING

    Kaposvár, 7400, Hungary

  • 30_TP Kék Pont Kecskemét_Blue Point Aquatherapy Ltd. (KomplexLabor site)

    RECRUITING

    Kecskemét, 6000, Hungary

  • 31_TP Szt Magdolna_Trial Pharma Ltd. Magdalene Private Hospital

    RECRUITING

    Budapest, 1023, Hungary

  • 32_OrthoSera_OrthoSera Medical Zrt.

    RECRUITING

    Budapest, 1123, Hungary

    Contact Email: •••••@•••••

  • 33_TP Fitt Harmony_Fitt Harmony Ltd

    RECRUITING

    Jászszentlászló, 6133, Hungary

    Contact Email: •••••@•••••

  • 34_BKS Hatvan_BKS Research Ltd. Albert Schweitzer Hospital and Outpatient Clinic

    RECRUITING

    Hatvan, 3000, Hungary

  • 36_CRU Encs_CRU Hungary Healthcare and Service Provider LLC.

    RECRUITING

    Encs, 3860, Hungary

    Contact Email: •••••@•••••

  • 37_KomplexLabor_KomplexLabor Diagnostics Ltd.

    RECRUITING

    Szeged, 6724, Hungary

    Contact Email: •••••@•••••

  • 38_Ganglion Orvosi Központ Nozologen Kft._Ganglion Medical Center

    RECRUITING

    Pécs, 7621, Hungary

    Contact Email: •••••@•••••

  • 39_TP Kecskemét_Trial Pharma Ltd. Kecskemét

    RECRUITING

    Kecskemét, 6000, Hungary

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.